The latest price target for Quest Diagnostics (NYSE:DGX) was reported by UBS on April 22, 2026. The analyst firm set a price target for $220.00 expecting DGX to rise to within 12 months (a possible 4.82% upside). 27 analyst firms have reported ratings in the last year.

The latest analyst rating for Quest Diagnostics (NYSE:DGX) was provided by UBS, and Quest Diagnostics maintained their neutral rating.

The last upgrade for Quest Diagnostics Inc happened on January 6, 2025 when Leerink Partners raised their price target to $174. Leerink Partners previously had a market perform for Quest Diagnostics Inc.

The last downgrade for Quest Diagnostics Inc happened on August 25, 2025 when Baird changed their price target from $194 to $194 for Quest Diagnostics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Quest Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Quest Diagnostics was filed on April 22, 2026 so you should expect the next rating to be made available sometime around April 22, 2027.

While ratings are subjective and will change, the latest Quest Diagnostics (DGX) rating was a maintained with a price target of $210.00 to $220.00. The current price Quest Diagnostics (DGX) is trading at is $209.88, which is out of the analyst’s predicted range.